Recovery · Compound

KLOW Blend

Four research peptides in one vial: KPV, GHK-Cu, BPC-157 and TB-500. What each was studied for, and what nobody has studied.

Philippines Peptides editorial deskUpdated Trial data checked 23 September 20266 min read

KLOW Blend is a research blend of BPC-157, TB-500, GHK-Cu and KPV. The blend itself has not been studied; each component's evidence is set out below.

What is KLOW Blend

KLOW Blend is a single lyophilised vial holding four research peptides together: KPV, a three-amino-acid fragment of alpha-melanocyte-stimulating hormone, plus the three peptides of GLOW Blend: the copper tripeptide GHK-Cu, the synthetic peptide BPC-157, and TB-500, a fragment related to thymosin beta-4.

Our partner and supplier Primara Labs lists its composition as: Lyophilized powder, KPV 10 mg + GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg / vial.

KLOW is sold as research material, not as a medicine, and no regulator has reviewed the four-peptide combination.

How it works

No mechanism exists for the blend as a whole, because nobody has studied it. The laboratory work is on each component alone.

KPV, the component KLOW adds, is the last three amino acids of alpha-melanocyte-stimulating hormone. In cell studies it enters intestinal and immune cells through the PepT1 transporter and dampens inflammatory signalling; a mouse study suggests this does not run through melanocortin receptors.

The proposed mechanisms of GHK-Cu, BPC-157 and TB-500, each from animal and cell work, are set out on the GLOW Blend page.

Benefits studied

KLOW Blend contains the three components of GLOW Blend (BPC-157, TB-500, GHK-Cu), whose findings are set out on that page, plus KPV, covered here.

KLOW Blend itself has not been studied as a combination. No trial, human or animal, has tested these components together. What follows is what research found for each component on its own, strongest evidence first.

KPV

Strongest evidence found: animal and cell.

  • Colitis

    Animal and cell

    In an animal study, mice with chemically induced colitis given KPV had less colitis and lower inflammatory cytokine expression. KPV has not been tested in people. Source: Gastroenterology 2008

  • Recovery from colitis

    Animal and cell

    In two mouse models of colitis, KPV-treated animals recovered sooner, regained more weight and showed less inflammatory infiltrate. This is animal evidence only. Source: Inflamm Bowel Dis 2008

  • Colitis-associated tumours

    Animal and cell

    In mice with colitis-associated cancer, KPV prevented tumours from forming, with no effect in mice lacking the PepT1 transporter. This is animal evidence only. Source: Cell Mol Gastroenterol Hepatol 2016

  • Oral mucositis

    Animal and cell

    In an animal study of chemotherapy-induced mouth ulcers in rats, KPV in an adhesive gel improved food intake and weight recovery. Source: Biomater Sci 2022

Side effects reported

As with its benefits, nothing is known about the side effects of KLOW Blend as a combination. The record for each component is below.

No human trial in the datasets reports adverse-event rates for KPV, which has been studied in animals and cells only. Without controlled data, its safety in people is unknown rather than established.

Regulatory status

BPC-157

FDA Philippines
No registered drug product found on the FDA verification portal.
US FDA
No record foundDrugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
European Medicines Agency
No record foundNo row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
Next milestone
No sponsor identified in any record read.

Checked 23 September 2026. Primary source

TB-500

FDA Philippines
No registered drug product found on the FDA verification portal.
US FDA
No record foundDrugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
European Medicines Agency
No record foundNo row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
Next milestone
No sponsor identified in any record read.

Checked 23 September 2026. Primary source

GHK-Cu

FDA Philippines
Not publishedCould not be established: the FDA Philippines verification portal search timed out on 23 September 2026, retried the same day in a browser with the same result.
US FDA
No record foundDrugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
European Medicines Agency
No record foundNo row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
Next milestone
No sponsor identified in any record read.

Checked 23 September 2026. Primary source

KPV

FDA Philippines
No registration found; FDA Advisory No. 2026-1013 warns against an unregistered KPV product.
US FDA
No record foundDrugs@FDA returned no approved or tentatively approved application for this substance. Drugs@FDA does not list investigational products. Separately, the FDA lists it on its page of bulk drug substances for compounding that may present significant safety risks (current as of 22 April 2026); that page concerns compounding, not approval.
European Medicines Agency
No record foundNo row for this substance in the EMA medicines report generated 22 September 2026. That report does not cover national authorisations in EU member states.
Next milestone
No sponsor identified in any record read.

Checked 23 September 2026. Primary source

How Philippine registration and prescription rules work, and what an unregistered product is under the law, is covered in the regulation hub, and every compound's status side by side is on the status page. This is general information, not legal advice.

FAQ

What is in KLOW Blend?

Four peptides in one vial. As listed by our partner and supplier Primara Labs: Lyophilized powder, KPV 10 mg + GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg / vial.

Has KLOW Blend been tested in people?

No trial, human or animal, has tested the four together. KPV itself has animal and cell data only; the evidence for the other three components is on the GLOW Blend page.

How is KLOW Blend different from GLOW Blend?

GLOW Blend is the same blend without KPV: GHK-Cu, BPC-157 and TB-500. See the GLOW Blend page.

Is KLOW Blend registered with FDA Philippines?

The regulatory records this site draws on hold no FDA Philippines registration for KLOW or for any of its four components; each component is listed in the regulatory section above. This is general information, not legal advice.

Where to get KLOW Blend in the Philippines

The supply index covers what to ask a seller before paying, and why quoted prices vary so widely.

View Supply Index

Risk · Disclosure · Editorial Status

This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.

In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.

Editorial Status
Non-clinical
Affiliation
Not a clinic · Not a pharmacy
Last Updated
September 23, 2026

Related peptides

Related guides

Updated